Navigation Links
The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
Date:12/10/2013

Suite 1650, San Francisco, CA 94105, 415-625-1100Silicon Valley/Monterey

675 North First Street, Suite 1100, San Jose, CA 95112, 408-490-2666North Bay

2455 Bennett Valley Road, Suite B204, Santa Rosa, CA 95404 707-544-4350


'/>"/>
SOURCE Leukemia & Lymphoma Society - Greater Bay Area Chapter
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
3. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
4. New Study Finds Targeted Treatment Can Significantly Reduce Relapse Risk In High-Risk Children With Acute Myeloid Leukemia
5. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
6. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
7. Polaris Group Files New IND for ADI-PEG 20 in Leukemia
8. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
9. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
10. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
11. The Leukemia & Lymphoma Society Issues Statement Regarding the Status of Iclusig (Ponatinib)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)... July 29, 2014   ... will present data from a Phase I clinical ... slow or stop Parkinson,s disease progression. The Michael J. ... grant and will discuss the impact of the results ... When:   Thursday, July 31, 2014     ...
(Date:7/29/2014)... Calif. , July 29, 2014  Drug ... amplified with rising incidence rates and the intense ... a preventative vaccine. Change is underway as the ... regimens towards highly effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... September 24 , - Novel Treatment ... and Reduction in Depressive Symptoms, Positive ... today at the 8th,European Congress of Epileptology, ... a novel once daily,anti-epileptic agent, significantly reduced ...
... Oral Insulin Capsule, ... on Type 1 Diabetics, JERUSALEM, Israel, September ... delivery systems, announced today that it has commenced Phase 2A,studies of ORMD ... Medical Center in Jerusalem, Israel., Oramed,s Phase 2A trial is focused ...
Cached Medicine Technology:New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 2New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 3New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 4New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 5New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 6Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics 2
(Date:7/29/2014)... (PRWEB) July 29, 2014 Helping people ... an immensely complex challenge that requires deep knowledge of ... to improve therapeutic options and outcomes has been the ... of biomedical engineering, since he joined the NJIT faculty ... significance is underscored by substantial funding from sources such ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Successful negotiations may depend ... with wider faces may have an advantage, according to a ... broader face are more successful when negotiating for themselves than ... may not be an asset when negotiations require collaboration and ... we think about it or not. It,s not just the ...
(Date:7/29/2014)... the nation,s largest interdisciplinary organization devoted to ... Bowers, PhD, RN, FAAN, of the University of Wisconsin-Madison ... Minority Issues in Gerontology Outstanding Mentorship Award. , This ... has exemplified outstanding commitment and dedication to mentoring minority ... presentation will take place at GSA,s 67th Annual Scientific ...
(Date:7/29/2014)... More Zeppelin than Zen, the Rock Spa® at ... having a complete renovation and, upon its re-opening in the ... and soul. , The Rock Spa® will include an all-new ... for experienced hair and nail stylists. Both part time and ... will be given full medical and health benefits, a rare ...
(Date:7/29/2014)... Oneida Nation Homelands, NY (PRWEB) July 29, 2014 ... Oneida Indian Nation have sent a letter to Washington NFL ... team representatives that opposition to the R-word racial slur is ... To date, the team and Snyder have yet to respond. ... to release the full text of the letter, which was ...
Breaking Medicine News(10 mins):Health News:Continuing the Quest for Better Stroke Therapies 2Health News:Continuing the Quest for Better Stroke Therapies 3Health News:Continuing the Quest for Better Stroke Therapies 4Health News:Wider Face May Give You an Edge in Negotiations 2Health News:Bowers to receive GSA's 2014 Minority Mentorship Award 2Health News:Rock Spa® at Seminole Hard Rock Hotel & Casino Tampa Prepares for Expansion 2Health News:Native American Groups Urge Washington Team Owner Dan Snyder to Stop Claiming Name Change Issue Driven by "Elites" Who Are Not People of Color 2
... 21 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, ... has closed its previously announced public offering (the ... $12.65 million. , The Company issued 73,333,333 Units ... "Offering Price"). The Company concurrently issued an additional ...
... Couples using assisted reproductive technology should be made aware, ... -- Compared to naturally conceived twins, those conceived through ... hospitalized and admitted to neonatal intensive care, finds a ... for all twins born in Western Australia between 1994 ...
... New White Paper Outlines Possible Ways to Improve ... Today, during a Partnership to Fight Chronic ... researchers Michael J. O,Grady, Ph.D., and James C. ... Projections for Diabetes and other Chronic Diseases: The ...
... Indicator of Demand for Well-Priced New and Refurbished ... Despite numerous negative earnings announcements, the demand ... to be robust during the current economic downturn. ... refurbished ultrasound solutions, reported a 118 percent increase ...
... May 21 CPC of America, Inc. (OTC Bulletin ... patent of a synthetic sealant for specific application to ... development and testing of the MedClose(TM) VCS, which is ... diagnostic and interventional procedures. In addition, CPC is ...
... May 21 Genomic Health, Inc. (Nasdaq: ... results from three studies at the American Society of ... - June 2, 2009, at the Orange County Convention ... widely-adopted Onco type DX(R) breast cancer test, which ...
Cached Medicine News:Health News:Response Biomedical Closes $12.65 million Unit Offering 2Health News:Response Biomedical Closes $12.65 million Unit Offering 3Health News:Response Biomedical Closes $12.65 million Unit Offering 4Health News:Fertility Treatment Twins More at Risk for Hospitalizations 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:MedPro Imaging Reports 118 Percent Growth For First Quarter 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 3Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Medicine Products: